表紙
市場調查報告書

腎上腺皮質癌症治療藥的全球市場:2019年∼2023年

Global Adrenocortical Carcinoma Drugs Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 895018
出版日期 內容資訊 英文 114 Pages
訂單完成後即時交付
價格
Back to Top
腎上腺皮質癌症治療藥的全球市場:2019年∼2023年 Global Adrenocortical Carcinoma Drugs Market 2019-2023
出版日期: 2019年07月23日內容資訊: 英文 114 Pages
簡介

腎上腺皮質癌症藥中,包含著大量的化療藥。2018年,化療藥部門獲得最大的市場佔有率,預計在預測期間內也將持續。這樣的存活率和有效性的增加等要素,在維持主要的市場地位上對化療藥部門有大幅貢獻。還有全球腎上腺皮質癌症治療藥市場,預計由於引起腎上腺皮質癌症的遺傳性疾病的罹患率增加,對法規上的優惠措施,及化療新藥的優勢等的市場成長要素在預測期間內6%以上的年複合成長率成長。然而,有效的治療方法的缺乏,試驗新治療藥的前臨床模式的缺乏,及藥物的副作用,可能妨礙預測期間的腎上腺皮質癌症藥產業的成長。

本報告提供全球腎上腺皮質癌症治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各類型

  • 市場區隔:各類型
  • 各類型比較:市場規模及預測(2018年∼2023年)
  • 化療
  • 標靶治療
  • 市場機會:各類型

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 對腎上腺皮質癌症的研究開發的增加
  • 腎上腺腫瘤影像技術的進步
  • 新的診斷法的登場

第12章 業者情勢

  • 概要
  • 創造性破壞狀況

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Laboratoire HRA Pharma SAS
  • Progenics Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31740

About this market

Adrenocortical carcinoma drugs significantly include chemotherapeutics. Technavio's adrenocortical carcinoma drugs market analysis considers sales from chemotherapy and targeted therapy segments. Our analysis also considers the sales of adrenocortical carcinoma drugs Asia, Europe, North America, and ROW. In 2018, the chemotherapy segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as increased survival rate and effectivity will significantly help the chemotherapy segment in maintaining its leading market position. Also, our global adrenocortical carcinoma drugs report has observed market growth factors such as increasing prevalence of genetic disorders leading to adrenocortical carcinoma, regulatory incentives, and advantages of novel drugs over chemotherapeutics. However, lack of effective therapies, lack of preclinical models for testing novel therapeutics, and side-effects of drugs may hamper the growth of the adrenocortical carcinoma drugs industry over the forecast period.

Overview

Advantages of novel drugs over chemotherapeutics

Novel therapies have minimal side effects and longer survival rate compared with chemotherapeutics. As a result, the development and approval of novel therapies are increasing, augmenting the sales of vendors. These factors will lead to the expansion of the global adrenocortical carcinoma drugs market at a CAGR of over 6% during the forecast period.

Advances in imaging techniques for adrenal tumors

Advances in imaging techniques are facilitating enhanced diagnostic accuracy for adrenocortical carcinoma in a non-invasive manner. This is assisting healthcare professionals in treating patients effectively by administering appropriate therapeutics and drugs. As a result, the sales of adrenocortical carcinoma drugs will increase. Therefore, this trend will have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global adrenocortical carcinoma drugs market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global adrenocortical carcinoma drugs market is concentrated. Technavio's robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading Adrenocortical carcinoma drugs manufacturers, which include Bristol-Myers Squibb Co., Eli Lilly and Co., Laboratoire HRA Pharma SAS, Progenics Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.

Also, the adrenocortical carcinoma drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Chemotherapy - Market size and forecast 2018-2023
  • Targeted therapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing R&D for adrenocortical carcinoma
  • Advances in imaging techniques for adrenal tumors
  • Emergence of new diagnostic methods

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • Laboratoire HRA Pharma SAS
  • Progenics Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Chemotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Targeted therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Key leading countries
  • Exhibit 37: Market opportunity
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Drugs under development
  • Exhibit 40: Vendor landscape
  • Exhibit 41: Landscape disruption
  • Exhibit 42: Vendors covered
  • Exhibit 43: Vendor classification
  • Exhibit 44: Market positioning of vendors
  • Exhibit 45: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 46: Bristol-Myers Squibb Co. - Business segments
  • Exhibit 47: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 48: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 49: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 50: Eli Lilly and Co. - Vendor overview
  • Exhibit 51: Eli Lilly and Co. - Business segments
  • Exhibit 52: Eli Lilly and Co. - Organizational developments
  • Exhibit 53: Eli Lilly and Co. - Geographic focus
  • Exhibit 54: Eli Lilly and Co. - Segment focus
  • Exhibit 55: Eli Lilly and Co. - Key offerings
  • Exhibit 56: Laboratoire HRA Pharma SAS - Vendor overview
  • Exhibit 57: Laboratoire HRA Pharma SAS - Key offerings
  • Exhibit 58: Progenics Pharmaceuticals Inc. - Vendor overview
  • Exhibit 59: Progenics Pharmaceuticals Inc. - Business segments
  • Exhibit 60: Progenics Pharmaceuticals Inc. - Organizational developments
  • Exhibit 61: Progenics Pharmaceuticals Inc. - Key offerings
  • Exhibit 62: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 63: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 64: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 65: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 66: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 67: Validation techniques employed for market sizing
  • Exhibit 68: Definition of market positioning of vendors
Back to Top